| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_0e77f06144be4708a6ae75bd9fee56a4 |
| classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K2121-00 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/B82Y5-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K51-1093
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K47-6897 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K38-43
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K47-48
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K49-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K39-395
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K51-10
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K51-00 |
| filingDate |
1993-03-03-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_e136d0117ae8fed29fdfa9ea5f8f2a59
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_7d0c17f55e6d707a0f62e29d9af81a2b
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_c0e0e829d351078df181053903a2baa7
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_5fd9633eaed43aef4ae52abcd828c3b3
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_e53ae24fcae7c6746b3e3261bb469476
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_dacb36de125542bc780ccad24d5b2095 |
| publicationDate |
1994-04-06-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
EP-0590109-A1 |
| titleOfInvention |
$i(IN VIVO) BINDING PAIR PRETARGETING |
| abstract |
Method for targeting in vivo to a patient a functional fraction by administration of a targeting fraction coupled to an affinity component, so that the targeting fraction has an affinity for the binding sites of the target zone, and by administration of a binding partner to the affinity component coupled to a functional fraction so as to localize the functional fraction in the target zone. Preferably, for performing in vivo imaging or therapy, the targeting fraction is an antibody and the functional fraction is a radioelement. The affinity component may be a new methotrexate analog. |
| priorityDate |
1992-03-04-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |